Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BIIB vs AMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BIIB Captures Overall Composite Edge (50.2 HOLD vs 48.9 HOLD), While AMD Leads 4–2 on Growth & Valuation Pillars

BIIB Overall Winner 6-Pillar Tally: BIIB 2 – 4 AMD Matrix Metrics: BIIB 6 – 4 AMD

As of Nov 16, 2026, Biogen Inc. (BIIB) captures the overall head-to-head institutional edge over Advanced Micro Devices (AMD) on higher Unified Composite conviction (50.2/100 HOLD vs. 48.9/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while AMD wins 4–2 across the 6-pillar growth and valuation breakdown. BIIB trades at $252.72 (15.6x Forward P/E, 23.5% operating margin) versus AMD at $508.41 (30.2x Forward P/E, 17.8% operating margin).

  • Growth vs. Quality Trade-Off: BIIB earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. AMD 48.9/100 HOLD) and 0.27β · 36% Vol risk profile, whereas AMD leads top-line expansion (+44.7% YoY revenue growth, 0.50x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BIIB vs AMD
BIIB NASDAQ Head-to-Head Winner
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
TTM Revenue $10.3B
Forward P/E 15.6x
Beta / 30D Vol 0.27β · 36% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 60.3 · SMA20: $250.29 · SMA50: $234.03
AMD NASDAQ
Advanced Micro Devices
Semiconductors & Related Devices
$508.41
-4.8% 1D
Market Cap $959.9B
TTM Revenue $45.4B
Forward P/E 30.2x
Beta / 30D Vol 3.60β · 118% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 23.0 Fund 42.0 Flow 68.0 Mom 37.6
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $517.43 · SMA50: $555.12

6-Pillar Scorecard Institutional Category Breakdown (BIIB 2 – 4 AMD)

Columns: Metric · BIIB · AMD
1. Valuation Multiples BIIB
Forward P/E 15.6x 30.2x
Trailing P/E 109.9x 125.1x
PEG Ratio 3.45x 0.50x
EV / Revenue 4.2x 21.2x
2. Growth & Scale AMD
Revenue Growth (YoY) +10.6% +44.7%
Earnings Growth (YoY) -84.8% +93.8%
TTM Revenue (USD) $10.3B $45.4B
Market Cap $37.0B $959.9B
3. Profitability & Quality BIIB
Gross Margin 75.8% 56.0%
Operating Margin 23.5% 17.8%
Net Profit Margin 3.4% 16.8%
Return on Equity (ROE) 1.9% 12.0%
4. Balance Sheet & Cash Flow AMD
Cash Generation (TTM) $1.64B $7.06B
Cash Flow Margin 16.0% 15.5%
Net Cash / Leverage $6.50B Net Debt (0.41x D/E) $1.51B Net Debt (0.13x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AMD
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 18.4% (6th %ile) 78.1% (10th %ile)
Put/Call OI Skew 0.77x (Call-Skewed) 1.07x (Balanced)
OBV Trend / Tech Phase ACCUMULATION · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat AMD
OpEx & R&D Intensity 52.3% of Rev ($5.39B) 38.2% of Rev ($17.4B)
90D R&D Disclosures 0 papers 7 papers
Competitive Moat Scale & Operating Efficiency Moat Concentrated Oligopoly Moat
Supply-Chain Role Drug Manufacturers - General Operator AI Accelerator & Server Chiplet Designer

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BIIB (6) vs AMD (4)
Institutional Metric BIIB AMD Criterion Row Edge
Market Capitalization
Scale
$37.0B $959.9B Larger Scale AMD
Trailing P/E Ratio
Valuation
109.9x 125.1x Lower Multiple BIIB
Forward P/E Ratio
Valuation
15.6x 30.2x Lower Multiple BIIB
Revenue Growth (YoY)
Growth
+10.6% +44.7% Higher Growth AMD
Operating Margin (TTM)
Profitability
23.5% 17.8% Higher Margin BIIB
Net Profit Margin
Profitability
3.4% 16.8% Higher Margin AMD
Return on Equity (ROE)
Capital Efficiency
1.9% 12.0% Higher ROE AMD
52-Week Range Position
Momentum
92% ($160–$261) 68% ($188–$659) Stronger Trend BIIB
Beta / 30D Volatility
Risk Regime
0.27β · 36% Vol 3.60β · 118% Vol Lower Realized Risk BIIB
Unified Institutional Score
Composite Signal
50.2 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite BIIB
Trailing 12M Revenue (USD)
Operating Scale
$10.3B $45.4B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 56.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.45x PEG · 4.2x EV/Rev 0.50x PEG · 21.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.64B ($6.50B Net Debt (0.41x D/E)) $7.06B ($1.51B Net Debt (0.13x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BIIB +12.48 pp
BIIB: +8.63% · AMD: -3.85%
3M Horizon BIIB +13.94 pp
BIIB: +18.9% · AMD: +4.96%
6M Horizon BIIB +10.92 pp
BIIB: +31.69% · AMD: +20.77%
1Y Horizon AMD +51.63 pp
BIIB: +53.41% · AMD: +105.04%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BIIB Revenue AMD Revenue BIIB Op. Margin AMD Op. Margin Margin Leader
FY2018 $13.4B $6.47B 43.8% 7.0% BIIB
FY2019 $14.4B $6.73B 49.0% 9.4% BIIB
FY2020 $13.4B $9.76B 33.8% 14.0% BIIB
FY2021 $11.0B $16.4B 25.9% 22.2% BIIB
FY2022 $10.2B $23.6B 29.9% 5.4% BIIB
FY2023 $9.84B $22.7B 11.8% 1.8% BIIB
FY2024 $9.68B $25.8B 16.9% 7.4% BIIB
FY2025 $9.89B $34.6B 13.1% 10.7% BIIB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BIIB CONSOLIDATION
17d in phase · OBV ACCUMULATION
Current IV 18.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AMD CONSOLIDATION
103d in phase · OBV ACCUMULATION
Current IV 78.1%
IV Percentile 10th %ile
Put/Call OI Skew 1.07x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor $500.00
Call Wall Magnet $600.00
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Put Floor: $500.00 (-1.7%) Spot: $508.41 Call Magnet: $600.00 (+18.0%)
  • Extended consolidation (103 days)
  • IV expanding (+13.4%) - uncertainty/bearish
  • Near put wall support ($500)

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BIIB Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $37.0B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($5.39B)
90D Engineering Disclosures 0 Published
AMD Moat Profile Concentrated Oligopoly Moat
AI Accelerator & Server Chiplet Designer
Data center GPU accelerators and server CPU chiplets scale directly with upstream leading-edge foundry utilization and cloud server integration.
OpEx & R&D Reinvestment 38.2% of Rev ($17.4B)
90D Engineering Disclosures 7 Published · LLM Efficiency / Architecture
Mapped Supply-Chain Ecosystem (18 partners):
Taiwan Semiconductor Manufacturing Company GlobalFoundries Samsung Electronics ASE Technology Holding
Active 90D Technical Topics:
Edge AI / Inference Chips Hardware-Agnostic ML Compilers Inference Serving / Speculative Decoding KV-Cache / Attention Memory Compression Mixture-of-Experts / Sparse Models

Investor FAQ BIIB vs AMD Key Questions & Quantitative Answers

As of Nov 16, 2026, Biogen Inc. (BIIB) captures the overall head-to-head institutional edge over Advanced Micro Devices (AMD) on higher Unified Composite conviction (50.2/100 HOLD vs. 48.9/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while AMD wins 4–2 across the 6-pillar growth and valuation breakdown. BIIB trades at $252.72 (15.6x Forward P/E, 23.5% operating margin) versus AMD at $508.41 (30.2x Forward P/E, 17.8% operating margin). Growth vs. Quality Trade-Off: BIIB earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. AMD 48.9/100 HOLD) and 0.27β · 36% Vol risk profile, whereas AMD leads top-line expansion (+44.7% YoY revenue growth, 0.50x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

AMD leads the Growth & Scale pillar: BIIB posts +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin), compared with AMD at +44.7% YoY revenue growth and +93.8% YoY earnings growth on $45.4B TTM revenue (56.0% gross margin, 17.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BIIB cumulative revenue shifted -26.5% while AMD shifted +435.4%. In operating R&D and SG&A reinvestment, BIIB deploys 52.3% of Rev ($5.39B) (0 90-day corporate R&D disclosures) versus 38.2% of Rev ($17.4B) (7 disclosures) for AMD.

BIIB screens cheaper on headline valuation multiples. BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin), whereas AMD trades at 30.2x Forward P/E, 125.1x Trailing P/E, 0.50x PEG, and 21.2x EV/Revenue (15.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BIIB (1.9% ROE) versus AMD (12.0% ROE) capital efficiency.

In options market volatility and institutional positioning, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk). By comparison, AMD carries 78.1% implied volatility (10th %ile, Compressed (<25th %ile)), a 1.07x (Balanced) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.60β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.